ECOR · electroCore, Inc.
$6.33
-0.07 (-1.09%)
At close · Jul 22
Going-concern doubt
— flagged May 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Notwithstanding the expected cash flow from operations and expected access to capital from existing and/or future debt and equity sources, the Company’s currently forecasted cash is less than the requirements to fund its operating expenses and capital expenditure requirements, as currently planned, for at least the next 12 months from the date the accompanying condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed May 6, 2026
Market Cap
$52.51M
Shares
8.30M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$32.03M
+27.2%
FY2025
Net Income
-$13.97M
-17.5%
FY2025
Gross Margin
86.75%
+1.8pp
FY2025
Operating Margin
-41.06%
+7.2pp
FY2025
Diluted EPS
-$1.65
-3.8%
FY2025
Operating Cash Flow
-$8.19M
-17.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $34.9M | $32.03M | $25.18M | $16.03M | $8.59M | $5.45M | $3.5M | $2.39M | $992.95K | $811.46K | |
| $4.45M | $4.24M | $3.79M | $2.8M | $1.62M | $1.39M | $1.74M | $1.16M | $578.74K | $518.53K | |
| $30.45M | $27.79M | $21.4M | $13.23M | $6.98M | $4.07M | $1.76M | $1.23M | $414.21K | $292.93K | |
| — | 86.75% | 84.97% | 82.51% | 81.19% | 74.59% | 50.3% | 51.6% | 41.71% | 36.1% | |
| $2.83M | $2.74M | $2.36M | $5.32M | $5.52M | $2.54M | $4.2M | $9.9M | $12.47M | $7.83M | |
| $42.26M | $38.21M | $31.2M | $27.17M | $24.33M | $21.57M | $21.84M | $35.42M | $42.5M | $18.11M | |
| — | $501K | $760K | $962K | $548K | $382K | $399.24K | $249.58K | $66.66K | $32.31K | |
| — | — | — | — | — | — | $464.61K | — | — | — | |
| $45.09M | $40.94M | $33.56M | $32.5M | $29.85M | $24.11M | $26.51M | $47.32M | $54.97M | $25.94M | |
| -$14.65M | -$13.15M | -$12.16M | -$19.27M | -$22.87M | -$20.04M | -$24.75M | -$46.09M | -$54.55M | -$25.64M | |
| — | -41.06% | -48.3% | -120.21% | -266.22% | -367.69% | -707.94% | -1928.17% | -5494.07% | -3160.31% | |
| — | -$12.65M | -$11.4M | -$18.31M | -$22.33M | -$19.66M | -$24.35M | -$45.84M | -$54.49M | -$25.61M | |
| $13.9K | $14.9K | $18.4K | — | $4000 | — | — | — | — | $6.3M | |
| -$1.01M | -$810K | $183K | $249K | $281K | $1.97M | $66.57K | $958.34K | -$1.21M | -$10.38M | |
| -$15.65M | -$13.96M | -$11.98M | -$19.02M | -$22.59M | -$18.07M | -$24.68M | -$45.13M | -$55.76M | -$36.03M | |
| — | $3000 | -$93K | -$186K | -$431K | -$851K | -$1.17M | $17.7K | $2431 | — | |
| -$15.38M | -$13.97M | -$11.89M | -$18.83M | -$22.16M | -$17.22M | -$23.51M | -$45.15M | -$55.82M | -$35.79M | |
| — | -43.6% | -47.2% | -117.49% | -257.94% | -315.87% | -672.55% | -1888.81% | -5621.66% | -4410.88% | |
| — | — | — | — | — | — | — | — | $55.01K | -$236.36K | |
| — | — | — | -$18.83M | -$22.16M | -$17.22M | — | — | — | — | |
| -$15.52M | -$13.98M | -$11.71M | -$18.83M | -$22.24M | -$16.95M | -$23.72M | -$45.25M | -$55.79M | -$35.94M | |
| USD/shares | — | -$1.65 | -$1.59 | -$3.42 | -$4.69 | -$4.36 | — | — | — | — |
| USD/shares | — | -$1.65 | -$1.59 | -$3.42 | -$4.69 | -$4.36 | — | — | — | — |
| shares | — | 8483 | 7483 | 5.52M | 4729 | 3945 | 2.6M | 1.96M | 1.95M | — |
| shares | — | 8483 | 7483 | 5.52M | 4729 | 3945 | 2.6M | 1.96M | 1.95M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 2.10×
EV/EBIT
—
Medical Devices median 21.00×
P/E (TTM)
—
Medical Devices median 27.41×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Bioelectronic Innovations Segment | $32,032,000 | $25,182,000 | — |
| Medical Devices Segment | — | — | $16,030,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| United States | $30,075,000 | $23,332,000 | $14,209,000 | $6,974,000 | $3,940,000 | $2,374,687 | $1,605,814 |
| United Kingdom | $1,695,000 | $1,666,000 | $1,571,000 | $1,296,000 | $1,344,000 | $1,051,206 | $665,627 |
| Other Countries | $197,000 | — | — | — | — | — | — |
| Japan | $65,000 | $65,000 | $102,000 | $139,000 | — | — | — |
| Germany | — | — | — | — | — | $53,925 | $102,427 |
| Other Countries | — | $119,000 | $148,000 | $183,000 | — | — | — |
| Other | — | — | — | — | $167,000 | $16,014 | $16,411 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Product | $31,967,000 | $25,117,000 |
| License | $65,000 | $65,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Bioelectronic Innovations Segment | -$13,153,000 | -$12,162,000 | — |
| Medical Devices Segment | — | — | -$19,269,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Bioelectronic Innovations Segment | -41.1% | -48.3% | — |
| Medical Devices Segment | — | — | -120.2% |